Novartis admits hiding thousands of serious Glivec, Tasigna side effects
This article was originally published in Scrip
Executive Summary
In hot water once again, Novartis Japan has confessed to having hidden 2,579 serious side effects cases relating to its cancer drugs Glivec (imatinib), Tasigna (nilotinib) and Afinitor (everolimus), including a fatality.